


PHARMACEUTICAL 2017

ELI LILLY & Co Rank 144 of 292









PHARMACEUTICAL 2017

ELI LILLY & Co Rank 144 of 292



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 87% points. The greatest weakness of ELI LILLY & Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 84%, being 81% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	15,101,400
Cost of Goods Sold	0
Intangible Assets	8,330,600
Liabilities, Current	10,986,600
Liabilities, Non-Current	13,738,800
Other Assets	7,121,300
Other Compr. Net Income	-645,100
Other Expenses	6,788,600
Other Liabilities	0
Other Net Income	0
Other Revenues	21,222,100
Property and Equipment	8,252,600
Research and Development	5,243,900
Selling, General and Administrative Expense	6,452,000

Output Variable	Value in 1000 USD
Assets	38,805,900
Liabilities	24,725,400
Expenses	18,484,500
Revenues	21,222,100
Stockholders Equity	14,080,500
Net Income	2,737,600
Comprehensive Net Income	2,415,050
Economic Capital Ratio	84%

